Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a daily glass of milk help ward off type 2 diabetes?

NCT ID NCT05421390

Disease control Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 11, 2026 · Last updated Aug 12, 2026 · Updated 1 time

Summary

This trial tests whether eating dairy products can improve how the body uses insulin in overweight and obese adults with prediabetes. Participants will be randomly assigned to eat either limited dairy (1 serving or less per day), reduced-fat dairy, or regular-fat dairy for 12 weeks. The study measures changes in insulin sensitivity using a precise test called a hyperinsulinemic-euglycemic clamp, along with other markers of glucose control and heart health.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Dairy products (reduced-fat and regular-fat)
What this could lead to
If dairy helps, it could offer a simple dietary strategy to improve insulin sensitivity and potentially delay or prevent type 2 diabetes in people with prediabetes.
What could go wrong
This is a small, early-stage trial, and results may not apply to everyone. The effect of dairy on insulin sensitivity is uncertain, and any benefit could be modest.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

60 people

The number who actually took part.

Started

Jun 2022

Finished

Oct 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

30 to 65 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Aged between 30 and 65 years, * Able to provide informed consent, * Stable weight and dietary habits over a period of 3 months, * Body mass index of 25-40 kg/m2, * Waist circumference ≥94 cm for men, ≥80 cm for women, * One or more indicators of prediabetes: 1. 5.7-6.4% HbA1c 2. fasting 5.6-6.9 mmol/L glucose, or 3. 7.8-11.0 mmol/L glucose at 2-h OGTT Exclusion Criteria: * Current smokers, * Pregnant or planning to become pregnant in the next 6 months, * Breastfeeding, * Participation in a weight loss program in the past 3 months, * Dairy allergy or lactose intolerance, * Any diagnosed eating disorders, * Substance abuse (drugs or alcohol \>3 drinks/day), * Diagnosed medical conditions such as cardiovascular disease, anemia, kidney disease, liver disease and any cancer, other than skin, within 5 years. * Diabetes diagnosis, * Abnormal electrocardiogram or chest X-Ray, * Treatment with diuretics, certain β-blockers, bronchodilators, daily nonsteroidal anti-inflammatory drugs, anticoagulants or antiplatelet agents (except prophylactic aspirin 81 mg/d), antianginals, antiarrhythmics, oral steroids, or other medications known to affect glucose metabolism, * Refusal to temporarily stop taking supplements (vitamin D, calcium, multivitamins, herbal remedies), * Serum creatinine \> 120 µmol/L, * Hemoglobin \< 120 g/L, * Liver function tests ≥ 2× upper limit, * Positive viral serology, * Inaccessible veins.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Glucose intolerance are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

glucose intolerance Insulin Resistance prediabetes syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Glucose intolerance Insulin sensitivity Prediabetes

Contacts and locations

Locations

  • RI-MUHC

    Montreal, Quebec, H4A 3J1, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.